[go: up one dir, main page]

AR063111A1 - Una formulacion farmaceutica de taxano - Google Patents

Una formulacion farmaceutica de taxano

Info

Publication number
AR063111A1
AR063111A1 ARP070104374A ARP070104374A AR063111A1 AR 063111 A1 AR063111 A1 AR 063111A1 AR P070104374 A ARP070104374 A AR P070104374A AR P070104374 A ARP070104374 A AR P070104374A AR 063111 A1 AR063111 A1 AR 063111A1
Authority
AR
Argentina
Prior art keywords
taxane
formulation
composition
pharmaceutical formulation
solid
Prior art date
Application number
ARP070104374A
Other languages
English (en)
Inventor
Lucio Nunez
Guillermo Moroni
Jose Iturraspe
Esteban Lorenzon
Original Assignee
Eriochem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eriochem Sa filed Critical Eriochem Sa
Priority to ARP070104374A priority Critical patent/AR063111A1/es
Priority to EP08836609.1A priority patent/EP2275092A4/en
Priority to PCT/ES2008/070178 priority patent/WO2009043956A1/es
Publication of AR063111A1 publication Critical patent/AR063111A1/es
Priority to US12/749,880 priority patent/US20100255104A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion farmacéutica de taxano para set administrada a mamíferos, preferentemente humanos, que comprende dos composiciones que se combinan previamente a su administracion formando una solucion transparente libre de precipitados y esencialmente libre de espuma, donde dichas composiciones comprenden una composicion solida de taxano y una composicion solubilizante de dicha composicion solida de taxano que comprende tensoactivo y antiespumante. Un kit para dicha formulacion de taxano inyectable que comprende una jeringa prellenada. Y una solucion farmacéutica de perfusion de taxano. Reivindicacion 2: La formulacion de la reivindicacion 1 caracterizada porque dicho agente antiespumante es seleccionado del conjunto comprendido por dimetilacetamida, dimetilsulfoxido alcohol bencílico, isopropanol, etanol o una mezcla de ellos.
ARP070104374A 2007-10-03 2007-10-03 Una formulacion farmaceutica de taxano AR063111A1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ARP070104374A AR063111A1 (es) 2007-10-03 2007-10-03 Una formulacion farmaceutica de taxano
EP08836609.1A EP2275092A4 (en) 2007-10-03 2008-10-01 PHARMACEUTICAL TAX FORMULATION
PCT/ES2008/070178 WO2009043956A1 (es) 2007-10-03 2008-10-01 Una formulación farmacéutica de taxano
US12/749,880 US20100255104A1 (en) 2007-10-03 2010-03-30 Pharmaceutical formulation of taxane

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP070104374A AR063111A1 (es) 2007-10-03 2007-10-03 Una formulacion farmaceutica de taxano

Publications (1)

Publication Number Publication Date
AR063111A1 true AR063111A1 (es) 2008-12-30

Family

ID=40225184

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104374A AR063111A1 (es) 2007-10-03 2007-10-03 Una formulacion farmaceutica de taxano

Country Status (4)

Country Link
US (1) US20100255104A1 (es)
EP (1) EP2275092A4 (es)
AR (1) AR063111A1 (es)
WO (1) WO2009043956A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
BR102015027955B1 (pt) 2014-11-11 2021-03-09 Colgate-Palmolive Company método de fabricação de uma composição para higiene bucal
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
BR112021005104A2 (pt) * 2018-10-16 2021-06-08 US Nano Food & Drug INC formulação de injeção intratumoral
CN116196283A (zh) * 2021-11-30 2023-06-02 深圳玖星制药有限公司 一种注射用紫杉烷类药物脂质体冻干粉剂的制备方法及原料组方
CN116350619B (zh) * 2021-12-28 2025-04-08 北京抗创联生物制药技术研究有限公司 一种口服紫杉烷类药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
HUP9701945A3 (en) 1997-11-10 2000-04-28 Hexal Ag Pharmaceutical composition for injection containing cyclodextrin and taxoids
US5922754A (en) 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
WO2000075281A2 (en) 1999-06-09 2000-12-14 University Technology Corporation Supercritical fluid-assisted nebulization and bubble drying
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
AU2002239282A1 (en) 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
ITMI20020680A1 (it) 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
KR100508518B1 (ko) 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit

Also Published As

Publication number Publication date
EP2275092A4 (en) 2013-05-01
US20100255104A1 (en) 2010-10-07
WO2009043956A1 (es) 2009-04-09
EP2275092A1 (en) 2011-01-19

Similar Documents

Publication Publication Date Title
ES2508290T3 (es) Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
AR063111A1 (es) Una formulacion farmaceutica de taxano
ECSP088239A (es) Composición de liberación de fármaco sostenida
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
CL2008001268A1 (es) Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor.
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
MX2008009358A (es) Una formulacion farmaceutica de taxano, una composicion solida de taxano, un procedimiento para la preparacion de dicha composicion solida de taxano, una composicion solubllizante de dicha composicion solida de taxano, y un conjunto de elementos (kit
BR112015017246A8 (pt) composição farmacêutica aquosa, seu uso e seringa
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
AR054064A1 (es) Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas
ECSP088240A (es) Composición de trazodona para administración una vez por día
CU23814A3 (es) Emulsión intravenosa de butilftalida y aplicación de la misma
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
BR112017026287A2 (pt) composições de hidroxipropil beta-ciclodextrina e métodos
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
AR080242A1 (es) Composiciones veterinarias. usos.
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
CO6251360A2 (es) Bromhidrato de bupropion y aplicaciones terapeuticas
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
BR112016001544A8 (pt) composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório
AR062737A1 (es) Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento
NO20025999D0 (no) Klart, vandig anestetisk preparat
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma

Legal Events

Date Code Title Description
FB Suspension of granting procedure